| St. Jude Medical, Inc. - SWOT Analysis company | | | | decrease of 31.3% over FY2007. |
| profile is the essential source for top-level company | | | | Scope of the Report |
| data and information. St. Jude Medical, Inc. - SWOT | | | | Provides all the crucial information on St. Jude Medical, |
| Analysis examines the company's key business | | | | Inc. required for business and competitor intelligence |
| structure and operations, history and products, and | | | | needs |
| provides summary analysis of its key revenue lines | | | | Contains a study of the major internal and external |
| and strategy. | | | | factors affecting St. Jude Medical, Inc. in the form of |
| St. Jude Medical is engaged in developing, | | | | a SWOT analysis as well as a breakdown and |
| manufacturing and distributing cardiovascular medical | | | | examination of leading product revenue streams of |
| devices for the global cardiac rhythm management, | | | | St. Jude Medical, Inc.-Data is supplemented with |
| cardiology, cardiac surgery and atrial fibrillation therapy | | | | details on St. Jude Medical, Inc. history, key |
| areas. The company also makes implantable | | | | executives, business description, locations and |
| neurostimulation medical devices for the management | | | | subsidiaries as well as a list of products and services |
| of chronic pain. The company markets its products in | | | | and the latest available statement from St. Jude |
| about 100 countries across the world. It primarily | | | | Medical, Inc. |
| operates in the US, Europe, Japan and Asia Pacific. It | | | | Reasons to Purchase |
| is headquartered in Saint Paul, Minnesota and employs | | | | Support sales activities by understanding your |
| 14,000 people. The company recorded revenues of | | | | customers' businesses better |
| $4,363.3 million during the financial year (FY) ended | | | | Qualify prospective partners and suppliers |
| January 2008, an increase of 15.5% over FY2007. | | | | Keep fully up to date on your competitors' business |
| The increase was due to higher sales of Implantable | | | | structure, strategy and prospects |
| Cardioverter Defibrillators ICDs, pacemakers and | | | | Obtain the most up to date company information |
| Atrial Fibrillation AF products. The operating profit of | | | | available |
| the company was $655 million during FY2008, a | | | | Table of Contents : |
| decrease of 17.4% over FY2007. The net profit of | | | | This product typically includes the following sections: |
| the company was $384.3 million in FY2008, a | | | | SWOT COMPANY PROFILE: ST. |